📚 Part of the Diabetes Landmark Trials guide — every landmark trial in one place.
Series: Landmark Trials in Endocrinology & Metabolism | Study #28
Category: Diabetes Prevention | Design: Long-term observational follow-up of the DPP RCT | n: 2,766 (88% of DPP cohort) | Follow-up: 10.0 years from original DPP randomisation (IQR 9.0–10.5)
📋 Summary
Authors: Diabetes Prevention Program Research Group (Knowler WC et al.)
Journal: Lancet 2009;374:1677–1686 | DOI: 10.1016/S0140-6736(09)61457-4
All active DPP participants were eligible for continued follow-up in the Diabetes Prevention Program Outcomes Study. Of these, 2,766 (88%) enrolled for a median additional follow-up of 5.7 years beyond the DPP’s 2.8-year intervention period. On the basis of DPP findings, all three original groups were offered group-implemented lifestyle intervention at the start of DPPOS, and participants in the original metformin group continued their assigned treatment unmasked. The original lifestyle group received additional lifestyle support. Diabetes incidence rates during the 2.8-year DPP were 4.8 per 100 person-years for lifestyle, 7.8 for metformin, and 11.0 for placebo. During the DPPOS follow-up, incidence rates converged to approximately 5.9, 4.9, and 5.6 per 100 person-years respectively as all groups received some lifestyle intervention. However, cumulative incidence from original randomisation to 10 years remained lowest in the lifestyle group. Over the full 10-year period, diabetes incidence was reduced by 34% (24 to 42%) in the lifestyle group and 18% (7 to 28%) in the metformin group compared with placebo. The weight loss achieved in the original lifestyle group was partially regained, while the modest weight loss in the metformin group was maintained. The cumulative incidence of diabetes remained significantly lower in the former lifestyle intervention group despite the post-DPP convergence of care.
📊 Key Findings
| Group | Incidence during DPP (per 100 PY) | Incidence during DPPOS (per 100 PY) | 10-year cumulative reduction vs placebo |
|---|---|---|---|
| Lifestyle (original) | 4.8 | 5.9 | 34% (24–42%) |
| Metformin | 7.8 | 4.9 | 18% (7–28%) |
| Placebo (offered lifestyle in DPPOS) | 11.0 | 5.6 | Reference |
| Rate convergence post-DPP | Near-complete convergence during DPPOS as all groups received lifestyle support | ||
| Cumulative incidence at 10 years | Lowest in original lifestyle group — maintained benefit | ||
DPPOS 10-Year Follow-Up
DPP follow-up · pre-diabetes · 10 years
Cumulative diabetes prevention persisted over 10 years from randomisation, with 34% (lifestyle) and 18% (metformin) reductions versus placebo despite post-DPP convergence of care.
💬 Expert Commentary
The DPPOS answers the most clinically pressing question left open by the DPP: does the benefit of early lifestyle intervention persist after the intensive programme ends, or does the incidence in the formerly protected group simply rise to catch up with the control rate? The answer is that cumulative protection is sustained. Despite partial weight regain in the original lifestyle group and near-complete convergence of diabetes incidence rates between groups during DPPOS, the cumulative incidence from original randomisation remained significantly and durably lower in the lifestyle group over 10 years — a diabetes prevention legacy effect that mirrors the metabolic memory concept established in DCCT/EDIC and the glycaemic legacy in UKPDS. This finding has important policy implications: even if intensive lifestyle programmes are not maintained indefinitely, the period of prevention achieved during the active programme translates into deferred diabetes onset with sustained absolute benefit in the affected cohort.
The metformin finding in DPPOS is also clinically significant. The 18% cumulative reduction over 10 years, achieved with a simple, low-cost, well-tolerated oral agent, represents a durable pharmacological prevention effect. The convergence of metformin and former-placebo incidence rates during DPPOS, when both groups received similar lifestyle support, suggests that metformin’s benefit in the DPP was additive to what is achievable with lifestyle alone rather than dependent on the metabolic momentum of the original intervention. The DPPOS data are now incorporated into international pre-diabetes management guidelines, which recommend both lifestyle modification and metformin (particularly in younger, heavier individuals at highest risk) for diabetes prevention, with the understanding that the benefits extend well beyond the active intervention period in the case of lifestyle and persist as long as metformin is continued.
Limitations: DPPOS was an observational follow-up with unmasking of assignments and post-DPP lifestyle support provided to all groups, which limits the contrast between original treatment allocations during the follow-up period. Weight loss in the lifestyle group was substantially attenuated compared with the original DPP intervention period. The study was funded by the NIH.
🔑 BOTTOM LINE
The DPPOS demonstrated that cumulative diabetes prevention from the DPP lifestyle intervention and metformin persists over 10 years from original randomisation, with 34% and 18% reductions respectively in cumulative diabetes incidence despite post-DPP convergence of care, establishing that early diabetes prevention interventions produce durable cumulative protection extending beyond the active intervention period.
⭐ Clinical Impact Rating: ●●●●○ Practice-supporting (confirmatory follow-up)